Variants of the CYP11B2 gene predict response to therapy with candesartan

European Journal of Pharmacology

Volumn 445, Issue 1-2, 2002, Pages 151-152

  Ortlepp, Jan R ^a   Hanrath, Peter ^a   Mevissen, Vera ^a   Kiel, Gerhard ^b   Borggrefe, Martin ^c   Hoffmann, Rainer ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Takeda Pharma GmbH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiotensin converting enzyme; CYP11B2; Pharmacogenetic

Indexed keywords

CANDESARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT OUTCOME;

AGED; ALDOSTERONE SYNTHASE; ANALYSIS OF VARIANCE; BENZIMIDAZOLES; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 0037036239     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01766-1     Document Type: Article

References (5)

1. Structural analysis and evaluation of the aldosterone synthase gene in hypertension
2. Associations between aldosterone synthase gene polymorphisms and the adrenocortical function in males
3. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients
4. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure
5. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels